Shukovski L, Tsafriri A
Department of Hormone Research, Bernhard Zondek Hormone Research Laboratory, Weizmann Institute of Science, Rehovot, Israel.
Endocrinology. 1994 Nov;135(5):2287-90. doi: 10.1210/endo.135.5.7525265.
Nitric Oxide (NO) is now recognized as a mediator of several biological functions. In the present study we examined the effects of NO synthase (NOS) inhibitors on the ovulatory process in vivo, and whether this effect can be reversed by a NO generator. Immature eCG-hCG treated rats were injected intraperitonealy (ip) or unilaterally into the periovarian sac (intrabursal injection; ib) with inhibitors of the inducible form of NOS. Aminoguanidine (AG) suppressed ovulation in a dose-dependent manner, reaching a 54% inhibition at a dose of 20 mg/kg when injected ip (p < 0.001 vs. saline control). Likewise, local ib administration inhibited ovulation from the treated ovary; thus a dose of 2 mg/kg resulted in 48% inhibition, as compared to the contralateral ovary (p < 0.01). Similar results were obtained whether AG was administered 2 h prior to the stimulation of ovulation by hCG or deferred up to 4 h afterwards. An additional NOS inhibitor, NG-methyl-L-arginine (L-NMA) suppressed ovulation, albeit to a lower extent. Intrabursal administration of L-NMA (0.1 and 1 mg/kg) resulted in 34% and 32% inhibition, respectively (p < 0.05 vs. the saline treated control). The same doses of NG-methyl-D-arginine (D-NMA) did not inhibit ovulation significantly compared to the saline treated control. When sodium nitroprusside (0.5 mg/kg), a NO generator, was injected concomitantly with AG, it completely reversed its inhibitory action on ovulation. Thus, we have demonstrated the ability of NOS inhibitors to suppress hCG-induced ovulation in the rat in vivo. The specificity of this effect is confirmed by the ability of a NO generator to reverse the inhibitory action of AG. In conclusion, the ovarian NO/NOS system seems to be necessary for follicle rupture during ovulation.
一氧化氮(NO)现已被公认为多种生物学功能的介质。在本研究中,我们检测了一氧化氮合酶(NOS)抑制剂对体内排卵过程的影响,以及这种作用是否能被一氧化氮供体逆转。对未成熟的经马绒毛膜促性腺激素(eCG)-人绒毛膜促性腺激素(hCG)处理的大鼠,腹腔注射(ip)或单侧注入卵巢旁囊(囊内注射;ib)诱导型NOS抑制剂。氨基胍(AG)以剂量依赖方式抑制排卵,腹腔注射20 mg/kg剂量时抑制率达54%(与生理盐水对照组相比,p<0.001)。同样,局部囊内注射也抑制了处理侧卵巢的排卵;因此,2 mg/kg剂量导致48%的抑制率,与对侧卵巢相比(p<0.01)。无论AG是在hCG刺激排卵前2小时给药还是延迟至刺激后4小时给药,均得到相似结果。另一种NOS抑制剂NG-甲基-L-精氨酸(L-NMA)也抑制排卵,尽管程度较低。囊内注射L-NMA(0.1和1 mg/kg)分别导致34%和32%的抑制率(与生理盐水处理对照组相比,p<0.05)。与生理盐水处理对照组相比,相同剂量的NG-甲基-D-精氨酸(D-NMA)未显著抑制排卵。当一氧化氮供体硝普钠(0.5 mg/kg)与AG同时注射时,它完全逆转了AG对排卵的抑制作用。因此,我们证明了NOS抑制剂在体内抑制大鼠hCG诱导排卵的能力。一氧化氮供体逆转AG抑制作用的能力证实了这种作用的特异性。总之,卵巢NO/NOS系统似乎是排卵过程中卵泡破裂所必需的。